## Clinical Context This patient demonstrates adverse effects from non-selective β-adrenergic antagonism: sexual dysfunction, fatigue, and peripheral vasoconstriction (cool extremities). His bradycardia (58 bpm) and inadequate BP control suggest either dose escalation is inappropriate or the drug class itself is poorly tolerated. ## Pharmacodynamic Rationale **Key Point:** Non-selective β-blockers (like atenolol) block β₁ (cardiac) and β₂ (vascular, metabolic) receptors. β₂ blockade causes: - Peripheral vasoconstriction → cool extremities - Impaired vasodilation → erectile dysfunction - Metabolic suppression → fatigue **High-Yield:** Dose escalation of a poorly tolerated agent worsens side effects without improving efficacy. The correct strategy is **drug class switch** to an agent with a different receptor mechanism. ## Management Algorithm ```mermaid flowchart TD A["Patient on β-blocker with adverse effects"]:::outcome --> B{"Adverse effects from β₂ blockade?"}:::decision B -->|"Yes: sexual dysfunction, fatigue, vasoconstriction"| C["Switch drug class"]:::action B -->|"No: inadequate BP control only"| D["Escalate dose or add agent"]:::action C --> E["CCB or ACE-I (different receptor)"]:::action E --> F["Counsel on mechanism & expected improvement"]:::action D --> G["Reassess in 2–4 weeks"]:::action ``` ## Why Switch Class? - **Calcium channel blockers** (amlodipine, diltiazem): block L-type Ca²⁺ channels → vasodilation without β₂ effects. No sexual dysfunction, no fatigue. - **ACE inhibitors** (lisinopril, enalapril): block angiotensin II formation → vasodilation + renal protection. No metabolic side effects. - Both are guideline-recommended first-line agents for hypertension. **Clinical Pearl:** Counselling the patient on the mechanism of side effects (receptor selectivity) improves adherence and sets realistic expectations for symptom resolution (2–4 weeks post-switch). [cite:KD Tripathi 8e Ch 31] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.